Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B14 | Q9BPX1 | 1/20 | 0.48 |
| ▸ | GPR6 | P46095 | 17/20 | 0.47 |
| ▸ | RBP4 | P02753 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4305205 | 0.84 | HSD17B14 (0.51) | HSD17B14 | |
| SCHEMBL4290403 | 0.83 | PRKCQ (0.44) | HSD17B14GPR6RBP4 | |
| SCHEMBL4290422 | 0.83 | PRKCQ (0.44) | HSD17B14GPR6RBP4 | |
| Hydrochloric Acid SCHEMBL4304166 | 0.82 | PRKCQ (0.43) | HSD17B14GPR6RBP4 | |
| Hydrochloric Acid SCHEMBL4304161 | 0.82 | PRKCQ (0.43) | HSD17B14GPR6RBP4 | |
| SCHEMBL3466796 | 0.82 | HSD17B14 (0.53) | HSD17B14 | |
| SCHEMBL3470360 | 0.80 | HSD17B14 (0.48) | HSD17B14 | |
| SCHEMBL3469936 | 0.79 | HSD17B14 (0.47) | HSD17B14RBP4 | |
| SCHEMBL3469979 | 0.78 | USP2 (0.52) | HSD17B14 | |
| SCHEMBL3467150 | 0.76 | HSD17B14 (0.50) | HSD17B14RBP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090197859-A1 | Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders | PFIZER INC. | 2009-08-06 | — | — | US | disclosed |
| US-20090197859-A1 | Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders | PFIZER INC. | 2009-08-06 | — | — | US | disclosed |
| US-20090197859-A1 | Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders | PFIZER INC. | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197859-A1 | Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders | HTR6, HTR5A, TPH1 | HSD17B14 2214/4885GPR6 39/4885RBP4 2013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.